EpiCept repeated recommendations AFTER REPORT (Direkt, news)
This is a Googel translation of a news release from the Swedish news agency "Direkt":
EpiCept repeated recommendations AFTER REPORT (Direct) 2011-08-17 12:40
LONDON (Reuters) Zacks reiterated its Outperform recommendation for EpiCept to the company's report. Although target price 2:50 U.S. dollars repeated, in an analysis update from August 16. The share was traded last at 0:48 dollars.
Dawson James describes the interim report as "encouraging" in a statement dated 16 August where repeated buy recommendations. The firm's price target is 1:50 of dollars in twelve months.
Rodman & Renshaw reiterate Outperform and target price $ 2 that the firm has had for a long time. The firm suggests that the FDA meetings, which is now approaching the second half of the current design of clinical trials for Ceplene and Amiket will provide guidance on the risk profile of the company and shares.
In addition to analyzing EpiCept is Rodman & Renshaw historically been commissioned to carry out private placements in connection with EpiCept's capital.
Edison, which has EpiCept as a customer, calculates the risk-adjusted present value of the company at $ 81 million, compared with a market capitalization of around 30 million and enterprise value (enterprise value) of just under 20 million dollars. No actual shares recommendation is however possible to deduce from the analysis.
Edison has since used a discount rate of 12.56 percent and industry standards for the probabilities that the research is successful.
Any milestone payments or initala payments for licensing agreements have not been included.
The analysis of financing has Edison estimated that the Company will need to seek new capital during the first half of 2012, provided that no licensing agreement is reached or milestone payments fell out.